OCR is a full-Vet CRO based in Lille-France, with others EU/US locations along with its affiliate Soladis Group (Paris, Basel, London, NYC, MASS, WDC, Toronto, Montreal) regrouping 150 people, with a know-how on every steps of the clinical development and registration of a product for the pets market. OCR is specialized in clinical studies on severe diseases affecting dogs and cats: cancer, and others diseases in therapeutic areas like inflammation, cardiology, dermatology, antibiotic resistance, neurology. Along with a highly experienced team (clinical project leaders, RCA, data managers, biostatisticians, and veterinary specialist consultants), OCR built clinical research trained network of veterinary clinics with high level technical platform, including imaging (CT-scan, MRI, scintigraphy) and radiation therapy units and vet specialist strongly involved in clinical research. Our expertise in a nutshell: conception of the study with vet experts, determining pre-clinical and clinical development plans, conducting Proof-of-Concept studies, Pilot and Pivotal studies, site selection, laboratory identification and management, regulatory affairs, data management & biostatistics, VICH GCP clinical studies standards. Strong track record with the vet industry with pilot/pivotal studies, as well as with biotech/pharma through comparative medicine studies.


Book our Roundtable sessions through the Networking Tab:

Monday and Tuesday at 3.30pm ***Limited places available***

How comparative medicine “Pet-human’ approach can support the selection of innovative products for investment in Animal Health?

Comparative medicine with naturally occurring diseases in pet dogs is a common approach used by Human Biotech to verify their pipeline. The non-regulatory, GCP-like Proof-of-Concept (PoC) studies provide solid data on a real-life pet model to support their decision making.

The Animal Health industry can benefit from scouting innovation in Human Biotech and use their programme to identify the promising products ready to enter to the animal clinical phase of development.

The roundtable will address:

  • General strategy to implement comparative medicine PoC study in Europe:
    • Study design methodology from idea to protocol preparation
    • Regulatory landscape
    • Ethical considerations
  • Examples of Human Biotech-Vet Players mutual benefit
  • Comparative/Translational pet model in oncology (Day 1)
  • Comparative/Translational pet model in other chronic diseases (Day 2)


Agata Rybicka Dr Agata Rybicka
Head of R&D
Dr Dominique Tierny Dr Dominique Tierny
Oncovet Clinical Research
Matthieu Dubruque Mr Matthieu Dubruque


Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

Randomized, double-blind trial of F14512, a polyamine- vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma

Tumor-associated macrophages influence canine mammary cancer stem-like cells enhancing their pro-angiogenic properties

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

Phase I dose escalation study of 12b80 – hydroxybisphosphonate linked doxorubicin – in dogs with naturally occurring osteosarcoma. Boyé P, David E, Le Bot R, Serres F, Marescaux L, Tierny D.

Aggressiveness potential of spontaneous canine mucosal melanoma can dictate distinct cancer stem cell compartment behaviors in regard to their initial size and expansion abilities. Touil Y; Segaoula, Z; Thuru X; Galiegue-Zouitina S; Tierny D; Quesnel B.

The role of a proprotein convertases inhibitor in reactivation of tumor associated macrophages and inhibition of glioma growth. Rose M, DuhamelM,Aboulouard S, Kobeissy F,Le Rhun E, Desmons A,  Tierny D, Fournier I, Rodet F, Salzet M.

The One Health Joint Action / Oncodays conference, for which OCR is co-organizer